Ophthalmology Doctors in New Rochelle, NY Accepting Medicare
10 Ophthalmology doctors found. Showing 1 - 10
 Dr. Franklin Leslie Bocian, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 140 Lockwood Ave, Suite 220, New Rochelle, NY 10801 Phone: 914-235-9500 Fax: 914-632-5501 |
Henry Stuart Levin, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 421 Huguenot St, New Rochelle, NY 10801 Phone: 914-632-7882 Fax: 914-632-3702 |
Aaron Howard Cohen, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 140 Lockwood Ave Ste 220, New Rochelle, NY 10801 Phone: 914-235-9500 Fax: 914-632-5501 |
Dr. Jay I Lippman, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 828 Pelhamdale Ave, New Rochelle, NY 10801 Phone: 914-636-3600 Fax: 914-636-2118 |
 Dr. Irina I Donev, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 175 Memorial Highway, Suite 1-5, New Rochelle, NY 10801 Phone: 914-636-1035 Fax: 914-636-1080 |
Dr. Bradley Hal Scharf, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 140 Lockwood Ave, Suite 220, New Rochelle, NY 10801 Phone: 914-235-9500 Fax: 914-632-5501 |
Lloyd W Lateiner, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 14 Lawton Street, 2nd Floor, New Rochelle, NY 10801 Phone: 914-235-8886 Fax: 914-632-1326 |
Dr. Marvin Sperling, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 135 Wykagyl Ter, New Rochelle, NY 10804 Phone: 914-907-7007 |
Dr. Robert H Baker, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 175 Memorial Hwy, Suite 1-9, New Rochelle, NY 10801 Phone: 914-633-4543 Fax: 914-633-4606 |
Dr. Harris Charles Brustein, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 77 Quaker Ridge Road, Suite 203, New Rochelle, NY 10804 Phone: 914-235-0022 Fax: 914-636-2722 |
News Archive
FDA assigns BYDUREON new PDUFA action date of October 22, 2010
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.
Gender-specific group therapy effective in treating depressed women with Type 2 diabetes
Gender-specific group therapy is effective for treating depressed women with Type 2 diabetes, according to a study published in the latest issue of the Annals of Behavioral Medicine and funded by the National Institute of Nursing Research.
Researchers discover molecular pathway in blood vessels that controls blood pressure and vascular function
University of Iowa researchers have identified a molecular pathway in blood vessels that controls blood pressure and vascular function and may help explain why certain drugs for type II diabetes also appear to lower patients' blood pressure.
Avicena files composition of matter patent application for treatment of Parkinson's disease
Avicena Group, Inc. has announced that it has filed a composition of matter patent application with the United States Patent and Trademark Office to cover potential treatments for Parkinson's disease, a progressive neurodegenerative disease.
› Verified 7 days ago
Internal Medicine
Anesthesiology
Pediatrics
Psychiatry & Neurology
Surgery
Obstetrics & Gynecology
Emergency Medicine
Cardiovascular Disease
Ophthalmology
Physical Medicine & Rehabilitation